Zoptarelin doxorubicin

Drug Profile

Zoptarelin doxorubicin

Alternative Names: AEZS-108; AN-152; D-81858; Doxorubicin-GnRH agonist conjugate; ZEN-008; Zoptrex

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator Tulane University
  • Developer AEterna Zentaris Inc; National Cancer Institute (USA); University of Southern California
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Endometrial cancer

Highest Development Phases

  • Phase III Endometrial cancer
  • Phase II Breast cancer; Ovarian cancer
  • Phase I/II Prostate cancer
  • Discontinued Urogenital cancer

Most Recent Events

  • 29 Mar 2017 Aeterna Zentaris completes clinical development of zoptarelin doxorubicin
  • 02 Feb 2017 University of Southern California and AEterna Zentaris completes phase I/II trial in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (NCT01240629)
  • 02 Feb 2017 AEterna Zentaris completes a phase III trial in Endometrial cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Czech Republic, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, Norway, Poland, Romania, Russia, Spain, Ukraine, United Kingdom (NCT01767155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top